You're three weeks into GLP-1 treatment. You eat a smaller lunch than usual — a handful of crackers and some fruit. Two hours later, you're shaky, sweaty, anxious, and suddenly ravenous. You check your glucose: 62 mg/dL. What happened?

This is reactive hypoglycemia — a post-meal blood sugar drop that occurs not because the medication pushed your glucose dangerously low, but because a mismatch between reduced food intake and insulin dynamics created a brief trough. It's more common than most GLP-1 patients realize, and it's almost always manageable with meal strategy.

Why this happens on GLP-1 therapy

GLP-1 receptor agonists are "glucose-dependent" insulin secretagogues — they stimulate insulin release only when blood glucose is elevated. This is why GLP-1 monotherapy (without insulin or sulfonylureas) carries very low hypoglycemia risk in clinical trials.

But reactive hypoglycemia is a different phenomenon. It occurs when:

The medication isn't causing dangerous hypoglycemia — it's amplifying a normal physiological pattern. Patients who dramatically reduce their food intake while eating high-glycemic foods in their remaining meals are most susceptible.

Recognizing the symptoms

Reactive hypoglycemia typically presents between 1.5 and 3 hours after eating. Symptoms include:

These symptoms typically resolve within 15–20 minutes of eating. If you experience them, consume 15 grams of fast-acting carbohydrate (4 oz juice, glucose tablets, a tablespoon of honey) and recheck symptoms in 15 minutes.

Not the same as feeling "low energy": General fatigue or brain fog on GLP-1s is common and usually related to reduced caloric intake. Reactive hypoglycemia is more sudden, more physical (shaking, sweating), and temporally linked to a meal 1–3 hours prior.

The meal strategy that prevents it

Preventing reactive hypoglycemia is straightforward once you understand the mechanism. The goal is to prevent the rapid glucose spike that triggers the overshoot:

When to involve your provider

Occasional reactive dips managed by meal strategy are normal and not clinically concerning. Contact your provider if:

Critical distinction: If you take insulin or a sulfonylurea alongside a GLP-1, hypoglycemia risk is significantly higher. Your prescriber should proactively reduce the dose of these medications when starting a GLP-1. If this conversation hasn't happened, initiate it.

Need a provider who gets this right?

Compare 31 vetted telehealth platforms. Licensed clinicians, all 50 states.

Compare Providers →

Paid links · Compounded medications are not FDA-approved

For most GLP-1 patients not on insulin or sulfonylureas, reactive hypoglycemia is a nuisance, not a danger. It responds reliably to meal composition changes and resolves as you develop new eating patterns that match your reduced appetite.

Editor's Pick

Embody

Injectable semaglutide · Metabolic report · 1:1 clinical guidance

$149 /1st mo
Visit →

Paid link · Compounded · Not FDA-approved

Sesame Care

Brand-name FDA-approved medications only · Pay-per-visit from $29

$29 consult
Visit →

Paid link · Brand-name FDA-approved medications